I. Bayani game daESMOJagorar 2025
A watan Agusta na 2025, ESMO ta fitar da wata sabuwar takardar shaidar cutar kansar huhu ta farko da ta ci gaba a cikin gida: Jagorar Aikin Asibiti ta ESMO don gano cutar, magani da bin diddigi, wacce aka buga a cikin mujallar oncology ta farko Annals of Oncology. Wannan ita ce sabuwar sabuntawa ta farko tun bayan sigar 2017 kuma tana ba da cikakken bayani ga masu ilimin oncology a duk duniya.
Ciwon daji na huhu shi ne mafi yawan kamuwa da mace-mace a duk duniya. Kowace shekara, ana samun sabbin mutane sama da miliyan 2.2 da kuma mace-mace sama da miliyan 1.8, wanda hakan ya sanya ciwon daji na huhu ya zama babban abin da ke haifar da mace-mace masu alaƙa da ciwon daji a cikin maza da mata. Ciwon daji na huhu wanda ba ƙaramin ƙwayar cuta ba (NSCLC) ya kai kusan kashi 80-85% na duk masu fama da ciwon daji na huhu. Dangane da wannan mummunan yanayi, fitar da ƙa'idar 2025 ya haifar da sabbin ci gaban kimiyya a cikin aikin asibiti, tare da sabunta dabarun gwajin alamun cutar yana da matuƙar muhimmanci.
II. Fassarar Sabuntawa na Jagororin Muhimmanci
2.1 Gwajin Alamar Halitta: Daga "Zaɓi" zuwa "Muhimmanci"
Jagorar 2025 ta yi wani gagarumin sauyi na dabarun da ya shafi gwajin alamar halitta. Jagorar ta bayyana karara cewa gwajin alamar halitta yana da mahimmanci don yanke shawara kan magani ga marasa lafiya da ke fama da matakin IB-III NSCLC.
Wannan shawarar ta faɗaɗa gwajin ƙwayoyin halitta tun daga mayar da hankali kan marasa lafiya da ke fama da cutar zuwa ga waɗanda suka kamu da cutar a matakin farko, waɗanda za a iya cirewa. Babban manufar ita ce gano sauye-sauyen kwayoyin halitta da ke haifar da su da kuma samar da tushen kimiyya don maganin da ya dace. Jagorar ta kuma jaddada cewa ya kamata a tantance yuwuwar biopsy da hanyar gano cutar ta hanyar ƙungiyoyi daban-daban bisa ga halayen marasa lafiya da ƙari.
Dangane da takamaiman dabarun gwaji, jagorar ta ba da shawarar a fili cewa a yi gwajin kwayoyin halitta kafin yanke shawara kan tiyata, kuma aƙalla ya kamata ya rufe EGFR da ALK. Wannan ra'ayi na "gwaji a gaba" yana da matuƙar mahimmanci ga daidaiton rarrabuwa da kuma maganin NSCLC na matakin farko - daidaito da daidaiton sakamakon gwaji kai tsaye ke ƙayyade zaɓin maganin adjuvant na gaba.
2.2 Nasarorin da aka samu a fannin maganin cututtuka a matakin farko na NSCLC
Jagorar 2025 ta haɗa shaidu daga manyan nazarce-nazarce na asibiti da yawa don kafa ingantacciyar hanyar magani ga marasa lafiya da ke fama da cutar NSCLC ta farko-farko da ke nuna alamun cutar kanjamau.
Marasa lafiya da aka canza EGFR zuwa masu dauke da cutar:Dangane da gwajin ADAURA mai muhimmanci, allurar osimertinib bayan tiyata na tsawon shekaru uku ta zama mizanin kulawa na duniya ga marasa lafiya da ke fama da gogewar EGFR exon 19 ko maye gurbin exon 21 L858R. Gwajin ADAURA wani bincike ne na mataki na uku na duniya, wanda aka tsara shi bisa tsari daban-daban, wanda aka tsara shi bisa tsari, wanda ke kimanta inganci da amincin allurar osimertinib ga marasa lafiya da aka cire gaba daya daga matakin IB-IIIA EGFR-mutane. Binciken ya nuna cewa osimertinib ya inganta rayuwa ba tare da cututtuka ba da kuma rayuwa gaba daya idan aka kwatanta da placebo, yana kafa osimertinib a matsayin sabon ma'aunin kulawa ga wannan al'umma. Duk da haka, nazarin bincike na gwajin ADAURA ya nuna cewa kusan kashi 36% na dakatarwar magani da wuri ya faru ne sakamakon abubuwan da suka faru marasa kyau, kuma wani kashi 31% ya faru ne saboda shawarar mara lafiya. Wannan binciken ya nuna buƙatar yin gwajin asali daidai kafin magani don tabbatar da cewa an ba marasa lafiya magani da aka yi niyya wanda zai iya samun fa'ida mai dorewa.
Marasa lafiya masu ɗauke da ALK:Dangane da gwajin ALINA, maganin alectinib bayan tiyata na tsawon shekaru biyu yanzu shine ma'aunin kulawa. A cikin babban binciken gwajin ALINA mai lakabin mataki na uku, alectinib ya nuna fa'idar tsira ba tare da cututtuka ba a cikin yawan jama'a na mataki na II-IIIA, tare da rabon haɗari na 0.24. Bayanan da aka sabunta daga gwajin ALINA da aka gabatar a taron ESMO 2025 sun nuna cewa bayan shekaru ≥3 na bibiya, fa'idar DFS na alectinib ta kasance "mai dorewa kuma mai ma'ana a asibiti," tare da rabon haɗari na 0.36 a cikin yawan jama'a na mataki na II-IIIA. Sabbin rahotannin jimillar rayuwa na shekaru 4 da aka ruwaito sun kai 98.4%, ƙimar DFS na shekaru 4 shine 75.5%, kuma an inganta tsarin jijiyoyi na tsakiya DFS, ba tare da sabbin siginar tsaro ba. Waɗannan bayanai masu ƙarfi sun ƙara tabbatar da alectinib mai taimako a matsayin ma'aunin kulawa bayan cire ALK-positive NSCLC kuma suna nuna ƙimar gwaji mai kyau don gano irin waɗannan marasa lafiya.
Zaɓin hanyar gwaji:Jagororin ESMO na 2025 sun bayyana dalla-dallaGwaje-gwajen kwamitin RT-PCR masu yawatare da NGS, IHC, da FISH na tushen RNA a matsayin ɗaya daga cikin hanyoyin fasaha da aka ba da shawarar don gano haɗin ALK. Wannan yana nuna cewa babban buƙatar jagorar ita ce yin gwaji don jagorantar yanke shawara na asibiti, maimakon tilasta wani takamaiman dandamalin gwaji. Ga samfuran RT-PCR da aka mayar da hankali kan gano EGFR da ALK, wannan dabarar gwaji mai sassauƙa tana ba da hujja mai ƙarfi bisa ga jagora don amfani da su a cikin aikin asibiti.
III. Maganin Fasaha na Gwaji Mai Daidaito
Ka'idar 2025 ta ci gaba da gwaji zuwa matakin yanke shawara kafin tiyata, wanda ke ɗaga matsayin daidaito, hankali, da kuma damar shiga. Kayayyakin ganowa guda biyu da aka bayyana a ƙasa sun yi daidai da buƙatun jagorar daga mahangar fasaha.
3.1 Kayan Gano Canjin EGFR - Dandalin Fasaha na ARMS Mai Ingantaccen
Fasaha ta asali: Ingantaccen fasahar ARMS yana ba da damar faɗaɗa takamaiman jerin ƙwayoyin halitta masu ƙarancin yawa a kan babban asalin nau'in daji
Kariyar fasaha guda uku:
-Ingantattun ARMS → yana inganta gane maye gurbi
- Ingantaccen Enzymatic → yana narke asalin nau'in daji kuma yana wadatar da jerin maye gurbi
-Tsarin da ke toshe zafin jiki → yana hana faɗaɗawa ba tare da takamaiman bayani ba
Aiki: Jin daɗinMitar allele mai canzawa 1%
Kula da gurɓatawa: Tsarin sarrafawa na ciki da aka gina a ciki + enzyme na UNG yana hana gurɓatawa
Lokacin juyawa: Aikin bututun rufewa, kimaninMinti 120
Samfurin jituwa:Nama/na'urar biopsy ta ruwasamfurori → yana magance buƙatun "gwaji a gaba"
Rufewa:sauye-sauye 45a cikin EGFR exons 18-21, daidai da yankunan da aka nuna a cikin jagora (share exon 19 da exon 21 L858R)
Amfani da asibiti: Yana jagorantar maganin EGFR-TKI kai tsaye
Kayan Gano Fusion na EML4-ALK na MMT 3.2 – Maganin Gano Fusion na Tushen RNA
-Dandalin fasaha: RT-PCR mai tushen RNA - yana ba da fa'idodi na asali akan hanyoyin da suka dogara da DNA don gano haɗin kai
-Amfanin da aka dogara da RNA: Yana gano rubuce-rubucen haɗakar da aka bayyana kai tsaye, yana guje wa kurakurai na ƙarya yadda ya kamata
-Shaidun bincikeA cikin ƙarancin haɗin ALK, RT-PCR ya fi aminci fiye da gwaje-gwajen da aka yi bisa DNA
-Sanin hankali: Yana gano haɗuwa zuwaKwafi 20 a kowane martani
-Rufe nau'ikan bambance-bambancen: MurfiNau'ikan haɗin EML4-ALK guda 12 da aka saba amfani da su(gami da bambancin 1 ~33%; bambance-bambancen 3a/3b tare ~29%)
-Kula da aiki da gurɓatawa: Bututun rufewa, ~ mintuna 120; tsarin sarrafawa da aka gina a ciki + enzyme na UNG yana hana sakamakon ƙarya
-Daidaitawar kayan aiki: Ya dace da kayan aikin PCR na yau da kullun daban-daban
-Daidaita Jagora: Ya yi daidai da ƙa'idar ESMO sosai
IV. Daidaito Tsakanin Gwaje-gwajen da Shawarwarin Jagora
Kayayyakin gano cutar guda biyu sun yi daidai da ka'idar ESMO 2025 ta farko da ta ci gaba a cikin gida ta hanyar amfani da fasahar zamani ta cutar kansar huhu wacce ba ta da ƙananan ƙwayoyin halitta a cikin manyan ma'auni masu zuwa:
V. Kammalawa
Jagorar ESMO 2025 ta farko ta NSCLC ta gabatar da sabon zamani na ganewar asali da magani daidai, wanda aka mayar da hankali kan “gwaji a gaba, daidai gwargwado, da kuma inganta magani."Kit ɗin Gano Mutance na EGFR da kuma MMT EML4-ALK Fusion Detection Kit sun cika buƙatun jagorar don manufofi, lokaci, da daidaito ta hanyoyi daban-daban na fasaha."
Kayan aikin EGFR yana amfani da ingantaccen fasahar ARMS don gano sauye-sauye masu mahimmanci a cikin samfuran da aka ƙayyade, yana tallafawa duka nama da biopsy na ruwa don ba da damar "gwaji a gaba."
Kayan ALK an gina shi ne akan RT-PCR na tushen RNA, yana ba da fa'idodi fiye da hanyoyin DNA don gano haɗin kai, wanda ya dace da shawarar ESMO na bangarorin RT-PCR masu yawa don gwajin ALK.
Tare, waɗannan samfuran guda biyu suna samar da mafita ta gwaji daidai da ƙa'idar ESMO 2025, suna tallafawa maganin adjuvant na musamman don farkon matakin NSCLC.
Nassoshi:
- Zer A, Ahn MJ, Barlesi F, da sauransu. Ciwon daji na huhu na farko da na gida wanda ba ƙaramin ƙwayar halitta ba ne: Jagorar Aikin Asibiti ta ESMO don ganewar asali, magani da bin diddigi. Ann Oncol. 2025;36(11):1245-1262. doi:10.1016/j.annonc.2025.08.003
Lokacin Saƙo: Mayu-06-2026